Imatinib Mesylate Inhibits Telomerase Activity in Cancer Cells
Author Information
Author(s): Uziel O, Fenig E, Nordenberg J, Beery E, Reshef H, Sandbank J, Birenbaum M, Bakhanashvili M, Yerushalmi R, Luria D, Lahav M
Primary Institution: Felsenstein Medical Research Center, Beilinson Campus, Sackler School of Medicine, Tel Aviv University, Petah-Tikva, Israel
Hypothesis
Does imatinib mesylate affect telomerase activity in malignant cell lines?
Conclusion
Imatinib mesylate significantly inhibits telomerase activity and cell proliferation in various cancer cell lines.
Supporting Evidence
- Imatinib caused a dose-dependent inhibition of telomerase activity in multiple cancer cell lines.
- At 15 μM concentration, imatinib inhibited telomerase activity by approximately 75%.
- Cell cycle analysis showed that imatinib treatment led to a decrease in the S-phase and an accumulation of cells in the G2/M phase.
Takeaway
Imatinib, a cancer drug, helps stop cancer cells from growing by blocking a special enzyme called telomerase.
Methodology
The study used various cancer cell lines to assess the effects of imatinib on telomerase activity and cell proliferation through assays and cell cycle analysis.
Limitations
The study primarily focused on specific cell lines and may not generalize to all cancer types.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website